The global long-read sequencing market was valued at USD 0.98 billion in 2025. The market is estimated at USD 1.14 billion in 2026 and is projected to reach USD 4.65 billion by 2036, at a CAGR of 15.1% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering sequencing technologies, platform economics, clinical and population genomics demand, regulatory and reimbursement conditions, cost per genome, the competitive landscape, and future growth opportunities.
The market, also known as third-generation or single-molecule sequencing, includes the instruments, consumables, services, and software used to read single DNA or RNA strands that span thousands or even millions of bases. It covers nanopore sequencing, single-molecule real-time (SMRT) sequencing with its high-fidelity (HiFi) mode, and synthetic and mapped approaches that rebuild long-range information on short-read instruments. Products in scope range from sequencers, flow cells, SMRT Cells, and reagents to extraction and library kits for high-molecular-weight DNA, enrichment panels, sequencing services, and analysis software. Optical genome mapping, short-read products and services, and DNA extraction products not made for high-molecular-weight DNA are excluded.
Oxford Nanopore Technologies reported 2025 revenue of GBP 223.9 million, a rise of 24.2% at constant currency, with clinical revenue up 59.9% to GBP 29.8 million. PacBio reported 2025 revenue of about USD 160.0 million, up 4%, as consumables revenue hit a record of about USD 81.9 million while instrument revenue fell to about USD 53.8 million from USD 65.8 million, showing that growth now rests more on installed-base use than on new capital buying. In September 2025, Genomics England awarded contracts of about GBP 3.49 million to sequence at least 2,000 genomes on both Oxford Nanopore and PacBio technologies for the Babies in Focus cohort, which forms part of its Generation Study of genome sequencing for newborns and rare conditions.
Long reads still cost more per sample than short-read sequencing and need intact, high-molecular-weight DNA, which limits their use with degraded clinical material and formalin-fixed tissue and keeps short reads as the default for large screening projects and price-sensitive buyers. Instrument demand depends heavily on academic budgets: PacBio reported that its instrument revenue fell about 10% year over year in Q2 2026. Export controls and geopolitical tensions weigh on international providers as well, and Oxford Nanopore reported that its H1 2026 sales dropped 16% in China and 14% in the Middle East. Key challenges include competition from low-cost short reads and from mapped-read methods that run on instruments laboratories already own, price pressure from new Chinese platforms, and complex long-read data that calls for specialized analysis tools and validated clinical pipelines.
IVD-marked platforms and clinical assays are a significant opportunity in the long-read sequencing market, since they let laboratories detect structural variants, repeat expansions, and methylation in one test for rare disease, oncology, pharmacogenomics, and infectious disease; Oxford Nanopore has launched the AmPORE-TB tuberculosis assay with bioMérieux and partnered with Cepheid on automated pathogen sequencing. Full-length transcriptomics with single-cell and spatial methods, methylation reads without bisulfite conversion, and checks of plasmids, viral vectors, mRNA, and cell lines in drug manufacturing offer further openings. Key trends include benchtop systems that lower entry costs, combined long- and short-read portfolios, a shift toward consumables and utilization-driven revenue, and a more regional market as Chinese laboratories move to domestic platforms.
By technology, the long-read sequencing market is segmented into nanopore sequencing, single-molecule real-time (SMRT) sequencing, and synthetic & mapped long-read technologies. Nanopore sequencing is expected to hold the largest share in 2026, owing to Oxford Nanopore's large installed base and wide product range, devices that scale from portable units to high-throughput systems, and new nanopore entrants such as CycloneSEQ and Qitan Technology. It is also set to record the highest CAGR through 2036, supported by clinical adoption, IVD-marked products, new infectious disease assays, and rising use in biopharmaceutical and applied markets. SMRT sequencing keeps a strong position thanks to the accuracy of HiFi reads and the growing Revio and Vega base, while mapped-read technologies are growing from a small base after Illumina launched its TruPath Genome solution.
By offering, the long-read sequencing market is segmented into instruments, consumables (flow cells & SMRT Cells, sequencing reagents, and library preparation & sample extraction kits), services, and software & bioinformatics. Consumables lead in 2026, as flow cells and reagents are needed for every run, revenue recurs across the whole installed base, and PacBio posted record consumables revenue in Q4 2025 even as its instrument sales fell. Services are set to grow the fastest, because research institutions, population programs, drug developers, and clinical laboratories increasingly outsource long-read work instead of buying systems, and providers such as Novogene, which added Revio systems in Munich, are building capacity. Software and bioinformatics matter more as clinical users need validated pipelines.
By application, the long-read sequencing market is segmented into whole genome sequencing & de novo assembly, targeted sequencing, transcriptomics & isoform analysis, epigenetics & methylation analysis, metagenomics & infectious disease, and other applications. Whole genome sequencing & de novo assembly leads in 2026, as long reads are widely used for complete assemblies, structural variant detection, and population and rare disease studies such as the Genomics England program. Transcriptomics & isoform analysis is set to record the highest CAGR, since full-length reads capture whole transcripts, splice isoforms, fusions, and RNA modifications, and pairing them with single-cell and spatial methods is gaining ground in neuroscience, oncology, and immunology. Metagenomics & infectious disease is also growing strongly, helped by assays such as AmPORE-TB.
By end user, the long-read sequencing market is segmented into academic & research institutes, hospitals & clinical laboratories, pharmaceutical & biotechnology companies, sequencing service providers, and applied & public health laboratories. Academic & research institutes hold the largest share in 2026, as genome centers have long been the main buyers of long-read systems, own a large part of the installed base, and run most assembly, structural variation, and transcriptomics studies. Hospitals & clinical laboratories are set to grow the fastest, driven by rare disease, newborn, oncology, and infectious disease testing, IVD-marked platforms and clinical panels such as QIAGEN's QIAseq xHYB Long Read Panels, and accredited services such as Azenta's clinical long-read genome test in the U.S.
North America holds the largest share of the global long-read sequencing market in 2026, as the U.S. has a dense network of genome centers, academic medical centers, clinical laboratories, and life science companies, along with suppliers such as PacBio, Illumina, and Azenta Life Sciences. Azenta became the first commercial provider approved to offer a clinical long-read genome test in the U.S. in October 2024, using Revio instruments in a laboratory holding CLIA certification and CAP accreditation. Research funding pressure has slowed instrument purchases, so near-term growth in the region is likely to come from consumables, services, and clinical use.
Europe is set to grow at the highest CAGR, supported by national initiatives such as the Generation Study, public health systems, and strong research bases in the U.K., Germany, France, and the Netherlands, as well as the Nordic region. Oxford Nanopore reported 23% constant currency growth in its EMEAI region in H1 2026, and IVD-marked platforms give clinical laboratories regulatory-ready options. Asia-Pacific holds a significant share: Chinese laboratories are moving to domestic platforms from CycloneSEQ, now part of MGI Tech, and Qitan Technology, Singapore backs long-read work through its National Precision Medicine program and a joint laboratory of PacBio, A*STAR, and Macrogen, and genomics spending is rising in Japan, South Korea, Australia, and India. The Middle East & Africa draws on programs such as the Emirati Genome Program, while Latin America remains a smaller market built on academic research, public health genomics, and agriculture.
The long-read sequencing market is highly consolidated, with Oxford Nanopore and PacBio, the two established platform providers, generating most platform revenue, alongside Chinese entrants, short-read companies with long-range methods, service laboratories, and reagent and software suppliers. Companies compete on read length, accuracy, cost per genome, ease of use, sample needs, and clinical readiness, and their spending is going into cheaper chemistries, benchtop instruments, IVD-ready products, and deals with diagnostics firms. Recent moves include MGI Tech's acquisition of CycloneSEQ in March 2026, Oxford Nanopore's GridION Dx registration, PacBio's SPRQ-Nx chemistry, Illumina's TruPath Genome launch, Qitan Technology's QPinnacle2 sequencer, and QIAGEN's long-read enrichment panels released in July 2025.
Key companies profiled in the report include Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Illumina, Inc. (U.S.), MGI Tech Co., Ltd. (China), Qitan Technology Ltd. (China), Novogene Co., Ltd. (China), Azenta Life Sciences (GENEWIZ) (U.S.), Eurofins Scientific SE (Luxembourg), Macrogen, Inc. (South Korea), and QIAGEN N.V. (Netherlands).
The market, also known as third-generation or single-molecule sequencing, includes the instruments, consumables, services, and software used to read single DNA or RNA strands that span thousands or even millions of bases. It covers nanopore sequencing, single-molecule real-time (SMRT) sequencing with its high-fidelity (HiFi) mode, and synthetic and mapped approaches that rebuild long-range information on short-read instruments. Products in scope range from sequencers, flow cells, SMRT Cells, and reagents to extraction and library kits for high-molecular-weight DNA, enrichment panels, sequencing services, and analysis software. Optical genome mapping, short-read products and services, and DNA extraction products not made for high-molecular-weight DNA are excluded.
Oxford Nanopore Technologies reported 2025 revenue of GBP 223.9 million, a rise of 24.2% at constant currency, with clinical revenue up 59.9% to GBP 29.8 million. PacBio reported 2025 revenue of about USD 160.0 million, up 4%, as consumables revenue hit a record of about USD 81.9 million while instrument revenue fell to about USD 53.8 million from USD 65.8 million, showing that growth now rests more on installed-base use than on new capital buying. In September 2025, Genomics England awarded contracts of about GBP 3.49 million to sequence at least 2,000 genomes on both Oxford Nanopore and PacBio technologies for the Babies in Focus cohort, which forms part of its Generation Study of genome sequencing for newborns and rare conditions.
Market Dynamics
A major driver of the long-read sequencing market is the ability of long reads to resolve structural variants, repeat expansions, segmental duplications, and other complex regions that short reads often miss, even though these variants are linked to many inherited diseases, cancers, and differences in drug metabolism. Clinical use is a second driver, as long reads find causal variants in patients left undiagnosed after short-read tests; Oxford Nanopore reported clinical revenue growth of 35% in H1 2026, and IVD-marked systems such as GridION Dx and the CycloneSEQ G100-ER are now available in Europe. National genomics and newborn programs add large, steady sample volumes, while falling costs open the technology to smaller laboratories, as shown by PacBio's placement of 140 Vega benchtop systems in 2025, up from 7 in 2024.Long reads still cost more per sample than short-read sequencing and need intact, high-molecular-weight DNA, which limits their use with degraded clinical material and formalin-fixed tissue and keeps short reads as the default for large screening projects and price-sensitive buyers. Instrument demand depends heavily on academic budgets: PacBio reported that its instrument revenue fell about 10% year over year in Q2 2026. Export controls and geopolitical tensions weigh on international providers as well, and Oxford Nanopore reported that its H1 2026 sales dropped 16% in China and 14% in the Middle East. Key challenges include competition from low-cost short reads and from mapped-read methods that run on instruments laboratories already own, price pressure from new Chinese platforms, and complex long-read data that calls for specialized analysis tools and validated clinical pipelines.
IVD-marked platforms and clinical assays are a significant opportunity in the long-read sequencing market, since they let laboratories detect structural variants, repeat expansions, and methylation in one test for rare disease, oncology, pharmacogenomics, and infectious disease; Oxford Nanopore has launched the AmPORE-TB tuberculosis assay with bioMérieux and partnered with Cepheid on automated pathogen sequencing. Full-length transcriptomics with single-cell and spatial methods, methylation reads without bisulfite conversion, and checks of plasmids, viral vectors, mRNA, and cell lines in drug manufacturing offer further openings. Key trends include benchtop systems that lower entry costs, combined long- and short-read portfolios, a shift toward consumables and utilization-driven revenue, and a more regional market as Chinese laboratories move to domestic platforms.
Segment Analysis
The report analyzes the market by technology, offering, application, end user, and geography, helping stakeholders identify the most attractive areas for investment, product development, and partnering.By technology, the long-read sequencing market is segmented into nanopore sequencing, single-molecule real-time (SMRT) sequencing, and synthetic & mapped long-read technologies. Nanopore sequencing is expected to hold the largest share in 2026, owing to Oxford Nanopore's large installed base and wide product range, devices that scale from portable units to high-throughput systems, and new nanopore entrants such as CycloneSEQ and Qitan Technology. It is also set to record the highest CAGR through 2036, supported by clinical adoption, IVD-marked products, new infectious disease assays, and rising use in biopharmaceutical and applied markets. SMRT sequencing keeps a strong position thanks to the accuracy of HiFi reads and the growing Revio and Vega base, while mapped-read technologies are growing from a small base after Illumina launched its TruPath Genome solution.
By offering, the long-read sequencing market is segmented into instruments, consumables (flow cells & SMRT Cells, sequencing reagents, and library preparation & sample extraction kits), services, and software & bioinformatics. Consumables lead in 2026, as flow cells and reagents are needed for every run, revenue recurs across the whole installed base, and PacBio posted record consumables revenue in Q4 2025 even as its instrument sales fell. Services are set to grow the fastest, because research institutions, population programs, drug developers, and clinical laboratories increasingly outsource long-read work instead of buying systems, and providers such as Novogene, which added Revio systems in Munich, are building capacity. Software and bioinformatics matter more as clinical users need validated pipelines.
By application, the long-read sequencing market is segmented into whole genome sequencing & de novo assembly, targeted sequencing, transcriptomics & isoform analysis, epigenetics & methylation analysis, metagenomics & infectious disease, and other applications. Whole genome sequencing & de novo assembly leads in 2026, as long reads are widely used for complete assemblies, structural variant detection, and population and rare disease studies such as the Genomics England program. Transcriptomics & isoform analysis is set to record the highest CAGR, since full-length reads capture whole transcripts, splice isoforms, fusions, and RNA modifications, and pairing them with single-cell and spatial methods is gaining ground in neuroscience, oncology, and immunology. Metagenomics & infectious disease is also growing strongly, helped by assays such as AmPORE-TB.
By end user, the long-read sequencing market is segmented into academic & research institutes, hospitals & clinical laboratories, pharmaceutical & biotechnology companies, sequencing service providers, and applied & public health laboratories. Academic & research institutes hold the largest share in 2026, as genome centers have long been the main buyers of long-read systems, own a large part of the installed base, and run most assembly, structural variation, and transcriptomics studies. Hospitals & clinical laboratories are set to grow the fastest, driven by rare disease, newborn, oncology, and infectious disease testing, IVD-marked platforms and clinical panels such as QIAGEN's QIAseq xHYB Long Read Panels, and accredited services such as Azenta's clinical long-read genome test in the U.S.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 19 countries, the Nordic countries, and four rest-of-region groups. The regional analysis considers genomics research infrastructure, national population and newborn programs, clinical adoption, regulatory and reimbursement frameworks, and the presence of domestic and international platform providers.North America holds the largest share of the global long-read sequencing market in 2026, as the U.S. has a dense network of genome centers, academic medical centers, clinical laboratories, and life science companies, along with suppliers such as PacBio, Illumina, and Azenta Life Sciences. Azenta became the first commercial provider approved to offer a clinical long-read genome test in the U.S. in October 2024, using Revio instruments in a laboratory holding CLIA certification and CAP accreditation. Research funding pressure has slowed instrument purchases, so near-term growth in the region is likely to come from consumables, services, and clinical use.
Europe is set to grow at the highest CAGR, supported by national initiatives such as the Generation Study, public health systems, and strong research bases in the U.K., Germany, France, and the Netherlands, as well as the Nordic region. Oxford Nanopore reported 23% constant currency growth in its EMEAI region in H1 2026, and IVD-marked platforms give clinical laboratories regulatory-ready options. Asia-Pacific holds a significant share: Chinese laboratories are moving to domestic platforms from CycloneSEQ, now part of MGI Tech, and Qitan Technology, Singapore backs long-read work through its National Precision Medicine program and a joint laboratory of PacBio, A*STAR, and Macrogen, and genomics spending is rising in Japan, South Korea, Australia, and India. The Middle East & Africa draws on programs such as the Emirati Genome Program, while Latin America remains a smaller market built on academic research, public health genomics, and agriculture.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, long-read sequencing and product portfolios, strategic developments, and SWOT analyses.The long-read sequencing market is highly consolidated, with Oxford Nanopore and PacBio, the two established platform providers, generating most platform revenue, alongside Chinese entrants, short-read companies with long-range methods, service laboratories, and reagent and software suppliers. Companies compete on read length, accuracy, cost per genome, ease of use, sample needs, and clinical readiness, and their spending is going into cheaper chemistries, benchtop instruments, IVD-ready products, and deals with diagnostics firms. Recent moves include MGI Tech's acquisition of CycloneSEQ in March 2026, Oxford Nanopore's GridION Dx registration, PacBio's SPRQ-Nx chemistry, Illumina's TruPath Genome launch, Qitan Technology's QPinnacle2 sequencer, and QIAGEN's long-read enrichment panels released in July 2025.
Key companies profiled in the report include Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), Illumina, Inc. (U.S.), MGI Tech Co., Ltd. (China), Qitan Technology Ltd. (China), Novogene Co., Ltd. (China), Azenta Life Sciences (GENEWIZ) (U.S.), Eurofins Scientific SE (Luxembourg), Macrogen, Inc. (South Korea), and QIAGEN N.V. (Netherlands).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global long-read sequencing market.
- Explains how structural variant detection, clinical genomics, population and newborn programs, and falling platform costs are driving demand.
- Assesses the effect of cost per sample, sample quality needs, research funding pressure, and geopolitical restrictions on growth.
- Identifies high-growth opportunities across technology, offering, application, end user, and region.
- Tracks IVD-marked platforms, clinical assays, full-length transcriptomics, native methylation analysis, and mapped-read technologies.
- Benchmarks leading platform, service, and reagent companies by position, portfolio, and strategy.
- Supports product planning, partnering, and market entry decisions for platform makers, service providers, and investors.
Key Questions Answered
- How big is the global long-read sequencing market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are clinical adoption and IVD-marked products changing the demand base for long-read sequencing?
- How do nanopore, SMRT/HiFi, and mapped-read technologies compare on accuracy, throughput, and cost?
- Which technology, offering, application, and end-user segments will grow the fastest?
- How are population genomics and newborn sequencing programs influencing platform and service demand?
- How are domestic Chinese platforms and export controls reshaping regional demand?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using to strengthen their positions?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Long-Read Sequencing Market, by Technology
6. Long-Read Sequencing Market, by Offering
7. Long-Read Sequencing Market, by Application
8. Long-Read Sequencing Market, by End User
9. Long-Read Sequencing Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- Illumina, Inc.
- MGI Tech Co., Ltd.
- Qitan Technology Ltd.
- Novogene Co., Ltd.
- Azenta Life Sciences
- Eurofins Scientific SE
- Macrogen, Inc.
- QIAGEN N.V.
